The financials
Danaher Corporation by the numbers
Danaher Corporation (DHR) reported revenue of $6.26B in Q2 2026 (quarter ended June 26, 2026), up 5.5% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $870M (14% of revenue). For the full year FY2025, revenue was $24.6B (+2.9% year on year) and net income $3.61B. Its largest segment in 2026-Q2 was Diagnostics at $1.13B, 46% of the disclosed total, just ahead of Life Sciences at 31%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $6.26B | $5.94B | +5.5% |
| Gross profit | $3.61B | $3.52B | +2.5% |
| Operating income | $1.13B | $760M | +48% |
| Net income | $870M | $555M | +57% |
| Diluted EPS | $1.23 | $0.77 | +60% |
| Operating | Revenue | Share |
|---|---|---|
| Diagnostics | $1.13B | 46% |
| Life Sciences | $759M | 31% |
| Biotechnology | $583M | 24% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $2.47B (-0.16%)
Diagnostics grew +6.4% year on yearBiotechnology -4.7% year on year
Segment Latestquarter on quarteryear on year
- Diagnostics$1.13B$1.13BQoQ -11%year on year +6.4%-11%+6.4%
- Life Sciences$759.0M$759.0MQoQ +10%year on year -0.39%+10%-0.39%
- Biotechnology$583.0M$583.0MQoQ +11%year on year -4.7%+11%-4.7%
- Diagnostics--QoQ -year on year ---
- Life Sciences--QoQ -year on year ---
Diagnostics & Research
Ranks #23 of 29 by Smart Score